Intercure (INCR) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Intercure (INCR) over the past year, losing 36.4% versus a loss of 38.5%. Zhengye Biotechnology is the larger company by market cap ($82.0 million vs $77.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCR | ZYBT |
|---|---|---|
| Share price | $5.17 | $1.73 |
| Market cap | $77.57M | $81.99M |
| 1-day change | +2.99% | +50.45% |
| YTD return | +13.63% | +50.43% |
| 1-year return | -38.45% | -36.40% |
| 5-year return | -85.42% | — |
| EPS (TTM) | $-0.95 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $8.01 |
| 52-week low | $3.40 | $0.616 |
| Distance from 52-week high | -38.45% | -78.40% |
| Average volume | 21.73K | 5.10M |
| Shares outstanding | 15.00M | 47.39M |
| Employees | 285 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
INCR vs ZYBT FAQ
Which is bigger, Intercure or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $81.99M compared with $77.57M for Intercure (INCR).
Which stock has performed better over the past year, INCR or ZYBT?
ZYBT returned -36.40% over the past 12 months, compared with -38.45% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Intercure and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.